GRAIL, Inc.

NASDAQ:GRAL

Medical - Diagnostics & Research

Healthcare
$102.10 +3.20%

+$1.90 today

Market cap
$4.59B
Beta
3.16
P/E (TTM)
-6.3
EPS (TTM)
-$9.73
52W Low $29.95High $118.84

Volume 0.62M

Average 0.77M

GRAL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

GRAIL, Inc.NASDAQ: GRAL

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $47.43M rose 1.7% year over year, ahead of the -15.8% change in trailing-twelve-month research & development. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at -15.9% a year.

Context

  • Research & development amounted to 133.0% of revenue in FY2025, down 123.6 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1.7% holds above the trailing-twelve-month pace of -15.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$47.43M-1.2% QoQ
Last fiscal yearDec 2025
$195.79M-39.3% YoY
LTMJun 2026
$190.99M-15.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.7%——
1 year-39.3%——
3-year CAGR-15.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
195.79M USD
Year-over-year change
-39.3%
4-year CAGR
-19.2%

Research & Development vs competitors

How GRAL compares with its peers on the latest reported figures

  • GRAL's LTM Jun 2026 research & development of $190.99M is the 3rd highest of the 10 companies compared; the peer median is $59.21M.
  • Its year-over-year change of -15.8% is the lowest of 10, against a peer median of +9.5%.
  • Research & development amounts to 115.6% of revenue for GRAL, versus a peer median of 17.4%.
GRAL Competitors Peer median
Research & Development for GRAL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$787.38M +56.9%+25.4%29.1%
GHGuardant Health, Inc.LTM Sep 2026$386.67M +7.6%-0.9%30.2%
GRALGRAIL, Inc.LTM Jun 2026$190.99M -15.8%-15.9%115.6%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
WGSGeneDx Holdings Corp.LTM Jun 2026$83.32M +64.3%-5.8%18.3%
BLLNBillionToOne, Inc.LTM Jun 2026$59.21M +38.6%—14.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$55.69M +11.9%+23.1%17.4%
CSTLCastle Biosciences, Inc.LTM Mar 2026$53.69M +5.8%+4.9%15.8%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
Peer median (excluding GRAL) $59.21M+9.5%+5.9%17.4%

Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.61M55.55M93.11M125.6M147.17M
Cost of Revenue114.62M172M188.72M203.62M209.75M
Gross Profit(100M)(116.45M)(95.61M)(78.02M)(62.57M)
Gross Margin-684.4%-209.6%-102.7%-62.1%-42.5%
Research & Development460.21M329.58M338.75M322.38M195.79M
Selling, General & Admin234.06M296.44M362.56M367.82M275.8M
Operating Expenses1.17B5.33B1.42B2.11B471.59M
Depreciation & Amortization58.45M154.76M158.7M158.06M156.34M
EBITDA(1.21B)(587.7M)(638.22M)(610.17M)(378.16M)
EBITDA Margin-8259.0%-1058.0%-685.5%-485.8%-257.0%
Operating Income(1.27B)(5.44B)(1.52B)(2.19B)(534.16M)
Operating Margin-8659.6%-9798.2%-1627.6%-1743.0%-363.0%
Interest Income332K1.74M7.95M26.73M28.65M
Interest Expense00000
Other Income / Expenses90K1.5M7.75M26.8M(341K)
Income Before Tax(1.27B)(5.44B)(1.51B)(2.16B)(534.5M)
Pre-Tax Margin-8659.0%-9795.5%-1619.3%-1721.7%-363.2%
Income Tax Expense(17.48M)(42.29M)(41.95M)(135.36M)(126.15M)
Net Income(1.25B)(5.4B)(1.47B)(2.03B)(408.35M)
Net Margin-8539.4%-9719.3%-1574.2%-1613.9%-277.5%
EPS (Basic)(40.18)(173.87)(47.20)(63.54)(11.11)
EPS (Diluted)(40.18)(173.87)(47.20)(63.54)(11.11)
Weighted Avg Shares31.05M31.05M31.05M31.9M36.75M
Weighted Avg Shares (Diluted)31.05M31.05M31.05M31.9M36.75M

GRAIL, Inc.

NASDAQ:GRAL

Intrinsic Alpha fair value

Locked

Current Price

$102.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.